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PURPOSE: Multiple Sclerosis (MS) is a chronic condition managed by disease modifying 
pharmaceutical therapies (DMTs). Health care cost is increasing due to high prescription drug 
spending. The high cost of branded DMTs highlights the potential value of lower cost generic 
therapies. Using generic DMTs could reduce the spending in the prescription drug sector. 
Recently, generic glatiramer acetate (GA) that treats relapsing remitting multiple sclerosis has 
become available. Appropriate insurer policies and practices are imperative to promote the use 
and utilization of generics like GA. Notably, no study has specifically evaluated the differences in 
utilization uptake of branded vs generic GA among the major insurer categories. The purpose of 
this study is to establish whether i n s u r e r  type affects the rate of utilization uptake of branded 
vs generic GA. 
 
METHODS: Prescription claims data for branded or generic glatiramer acetate for 
Commercially insured patients, Medicare beneficiaries with supplemental insurance, and 
Medicaid patients were extracted from Symphony Health Integrated Dataverse® data set from 
Oct 2014 – Jan 2019. Patient claim cohorts were identified through branded Copaxone® 20 mg 
or 40 mg, generic Glatopa® 20 mg or 40 mg, and generic Mylan Glatiramer Acetate 20 mg or 40 
mg national drug codes. Data was limited to 52 months of claims data inclusive of FDA post-
approval of generic glatiramer acetate options. Projected glatiramer acetate utilization rates were 
estimated using exponential regression modeling. Patient out of pocket costs were captured as 
pharmacy transactional level insights from the patient’s primary plan pay setting of the initial co-
pay amount and additional plan pay from third-party utilization of copay cards subsidizing the 
prescription.  
 
RESULTS: From October 2014 to January 2019, 111,906 patients with multiple sclerosis were 
prescribed glatiramer acetate by Neurologists (80%) and had 1,624,159 approved dispensed 
claims primarily through specialty mail (87%) and categorized by payment type as 63.2% 
Commercial, 25.4% Medicare, and 11.8% Medicaid. The market trend showed a consistent 
decline in branded glatiramer acetate claims offset by a rapid uptake in generic glatiramer acetate 
with its initial market entry but remained relatively flat until launch of an additional generic 
market entrant. Generic market share has continued to grow reaching an approximate 30% share 
of claims. Over the 52 months brand glatiramer acetate utilization has declined more than half at 
56%, while generic claim volume has grown 155% over the past 16 months. Among the payer 
types, Medicare has observed the greatest brand decline at 70% and the second highest generic 
utilization uptake at a 28% share. Commercial insurers have the greatest category claim volume 
and greatest generic growth to a 26% share, while the brand has declined by 44%. Medicaid has 
had the lowest utilization volume and the greatest ratio of generic utilization among insurers at 
45%. Patient out of pocket costs are highest with branded use across all insurer types, while 
Medicaid has the lowest patient out-of-pocket costs. Across all payment types, generics offer 
approximately a 20% discount to the brand in patient out of pocket costs. 
 
CONCLUSION: The study revealed that generic glatiramer acetate adoption or utilization has 
been slow among insurers but increasing over the past sixteen months with additional generic 
GA entrants and increased price competition. The greatest trend in generic utilization is 
occurring within the Commercial channel followed by Medicare and Medicaid, which has had the 
lowest growth trend. The results indicate that barriers to generic glatiramer acetate may vary by 
insurer and influenced by prescriber or patient choice. Generic uptake is projected to increase 
across all insurer types reflective of trends during 2019 open enrollment and healthcare benefit 
design change associated with a new health insurance cycle. Lower patient out-of-pocket costs 
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and generic preferred formulary positioning will influence utilization rates, especially in 
beneficiaries or enrollees with the greatest financial cost shift risk. 
 
KEYWORDS: Benefit Design, Copaxone®, Drug Utilization, Formulary Management, Generic, 






Background of Glatiramer Acetate and Need for Analysis 
 
Multiple sclerosis (MS) is a chronic, autoimmune, neurological disease affecting the 
central nervous system caused by the demyelinating of neurons, which results in an inability of 
nerve cells to transmit signals and producing a wide variety of symptoms (Freedman, Selchen, 
Prat, & Giacomini, 2018). MS affects approximately 1 million people in the US (Wallin, 2019). 
Multiple sclerosis is associated with progressive disability, reductions in quality of life, and is a 
tremendous economic burden for patients, families, and society (Naci, Fleurence, & Birt, 2010). 
It has been reported that total all-cause health care costs associated with MS including direct and 
indirect costs in the United States ranged from $8,528 to $52,244 per patient per year (Adelman, 
Rane, & Villa, 2013). 
In the absence of a cure, MS therapy consists primarily of supportive care and 
symptomatic management, which may generate substantial direct costs. A mainstay for treatment 
is disease-modifying therapies (DMTs) or medications that alter immune response. With 
appropriate use of these DMTs, significant clinical benefit may be realized by slowing 
progression or altering the course of various forms of the disease. DMTs are considered specialty 
pharmaceuticals, a category associated with insurance restrictions like prior authorization, step 
therapy, formulary tiers and co-insurance due to their high cost, complexity of the disease they 
treat, and the need for enhanced clinical services to ensure safe use of the drug and to optimize 
therapeutic outcomes (Penington & Stubbings, 2016). Amongst these DMTs, Copaxone® or 
glatiramer acetate stands out due to its unique mechanism of action and demonstrated extensive 
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clinical experience supporting its efficacy, safety, and generally good patient tolerability 
(Caporro, Disanto, Gobbi, & Zecca).  
Copaxone® has also been recognized as the DMT with the highest cost increases at 
greater than 1000%, which far exceeds standard prescription inflation rates. Branded Copaxone® 
initial cost when launched in 1996 was $9,000 a year and now has increased to over $85,000 a 
year contributing to higher cumulative direct healthcare costs (Hartung, Bourdette, Ahmed, & 
Whitham, 2015). In fact, recent research has found that most MS DMTs have increased in 
acquisitions cost to approximately $80,000 per patient per year (Hartung, Johnston, & Bourdette, 
2018). The research confirms that the cost to treat MS with DMTs is extremely high. By itself, 
MS ranked eighth by drug invoice spending among the top therapeutic classes in the U.S. in 
2016, representing nearly $19 billion in drug spending alone (IQVIA, 2017). The introduction of 
these expensive specialty DMTs for the treatment of MS has created the potential for patients 
with MS to become higher contributors to healthcare spending (Anderson & Philbrick, 2014). 
Specialty drugs have become a major driver of prescription drug costs for insurers as well as out-
of-pocket expenses borne by the patient. Since about half of specialty drug spending is on self-
administered agents covered under the pharmacy benefits, these have been the focus of payer 
efforts to control spending. Insurers and pharmacy benefit managers seeking to manage costs 
have largely been unable to use the traditional 3-tiered cost-sharing design to encourage 
utilization of lower-cost drugs since specialty drugs often have few close, less-expensive 
substitutes until recently. 
The primary patent for Teva’s brand Copaxone® (glatiramer acetate) 20 mg daily ended 
in May 2014. Its expiration or invalidation of remaining patents created the opportunity to 
develop generic alternatives, which could result in cost savings for patients and payers. 
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Following submission of an ANDA in December 2007, the first generic glatiramer acetate named 
GLATOPA® was approved by the FDA in April 2015, based on demonstration of equivalent 
physicochemical characteristics plus immunologic and clinical effects to Copaxone®. 
Subsequently, the Glatopa® 40 mg generic formulation was approved in February 2018. In 
parallel, Mylan Pharmaceuticals received approval of its 20 and 40 mg generic versions of 
glatiramer acetate in October 2017. Both generic versions were introduced at wholesale 
acquisition cost discounts of between 15 to 70% discount to branded Copaxone®. Generic drugs 
are one of the most effective checks on rising drug costs in the United States (Kohl & Shrank, 
2007). Thus, the current MS treatment landscape may change with the approval of less expensive 
generic versions of DMTs for MS. 
Reducing the cost of MS DMTs would have a significant impact on the cost-effectiveness 
of these drugs and patient costs (Owens, 2016). With increased availability and development of 
less expensive generic specialty pharmaceuticals, US insurers can implement appropriate 
prescription management strategies to control both overall utilization and costs within the MS 
category if they should choose. Key insurer management strategies for specialty pharmaceuticals 
could include the implementation of specialty tiers and complex formulary designs, drug 
restrictions through prior authorizations and quantity limits, co-payments and co-insurance rates 
that increase patient cost burden, and government regulation for pharmaceutical step-therapy 
interventions and drug price controls (Patel & Audet, 2014). Moreover, insurers may implement 
specialty pharmacy provider dispensing for drug distribution, medication therapy management 
programs to increase coordination of care, quality measures enforced through healthcare reform 
and accountable care organizations and increased use of evidence-based medicine. 
Many insurers have already adopted incentive-based formularies to control prescription-
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drug costs through generic utilization in other therapeutic categories. An incentive based, or 
tiered formulary provides financial incentives (i.e., lower copayments) for enrollees to choose 
drugs that are preferred by the payer. Different changes in formulary administration may have 
dramatically different effects on utilization and spending and may in some instances lead 
enrollees to discontinue therapy. The associated changes in copayments can substantially alter 
out-of-pocket spending by enrollees, the continuation of the use of medications, and possibly the 
quality of care (Happe, Clark, Holliday, & Young, 2014). 
Differences in benefit design between insurer types (Commercial, Medicare, and 
Medicaid) and differences in patient out of pocket costs may lead to variations in the rate of 
utilization uptake of generic vs branded glatiramer acetate among patients depending on the 
type of insurance. Little is known regarding the impact or use of generic treatments in MS. 
Insight into MS market dynamics is important as it provides an opportunity to assess 
management and utilization of generic prescription medications in MS through insurance 
benefit design. 
Problem Statement 
This study investigates the utilization uptake of generic vs. branded glatiramer acetate in 
multiple sclerosis (MS) using prescription claims data to highlight any differences in uptake 
between the three primary insurance payer types through benefit coverage and design. The 
primary insurance types include Commercially insured, Medicare, and Medicaid payers. This is 
an important area of research because there are no studies examining current utilization 
incentives used by insurers to facilitate generic glatiramer acetate uptake as covered 
beneficiaries. Literature articles indicate that MS imposes a significant economic burden on 
patients and the US healthcare system utilization. MS prescription drug costs have risen in a 
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dramatic fashion. The cost of MS drugs in the United States is rising five to seven times faster 
than the normal rate of drug inflation (Hartung, Bourdette, Ahmed, & Whitham, 2015). 
Therefore, insurers have introduced multiple formulary reforms and initiatives to optimize the 
managed entry of new drugs, in addition, to help control expenditure of existing drugs through 
the encouraged use of prescription generics leveraging lower cost and increased competition. 







Does generic glatiramer acetate availability lead to greater utilization among insurers in 




This is an archival data analysis of U.S. patients with multiple sclerosis that are 
Commercially insured, Medicare, and Medicaid beneficiary cohorts identified by branded or 
generic 20 mg or 40 mg glatiramer acetate utilization analyzed through de-identified claims data 




Increasing healthcare expenditure has led healthcare authorities, providers, and patients to 
minimize costs and maximize savings relative to outcomes (Burke & Ryan, 2014). Brand 
medication cost is a key component from both an affordability and accessibility perspective 
(National Academies of Sciences, Engineering, and Medicine, 2017). Upon patent loss by the 
originator of a branded drug, generic drug entry is soon to follow pending FDA approval. The 
FDA has approved two generic forms of glatiramer acetate on the basis that they are bioequivalent 
to the brand. Generic drugs are usually priced at a discount to the originator and thus offer direct 
acquisition cost savings to the payer and patient savings in the form of lower copayments (Landon 
et al., 2007).  Switching from branded to generic medication use is a common cost containment 
measure. Drug insurance plans typically encourage preferred vs non-preferred drug use through 
tiered pharmaceutical formularies to guide prescription-drug use, requiring relatively small patient 
copayments for inexpensive generic drugs and higher copayments for brand-name drugs 
(Kouvelis, Xiao, & Yang, 2015). 
Pharmaceutical manufacturers, however, use coupons to reimburse patients for this 
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difference in copayments when they buy brand-name medications, so that, for people with 
commercial insurance coverage, the out of pocket costs are the same as those for generic drugs. 
Patients with commercial insurance like the coupons because they can help make expensive 
brand-name drugs more affordable. But the coupons may also discourage patients from 
considering appropriate lower-cost alternatives, including generics. It is however illegal under 
the federal anti-kickback law for drug manufacturers to offer any type of payment that might 
persuade a patient to purchase something that federal health care programs like Medicare and 
Medicaid might reimburse. Pharmaceutical manufacturers may sponsor patient assistance 
programs (PAPs) that provide financial assistance or drug free product (through in-kind product 
donations) to low income individuals to augment any existing prescription drug coverage. PAPs 
also can aid Part D enrollees and interface with Part D plans by operating "outside the Part D 
benefit" to ensure separateness of Part D benefits and PAP assistance. Theses Medicare Savings 
or Extra Help Programs can help pay for patient premiums and out-of-pocket costs, such as 
deductibles and coinsurance. Medicare currently identifies products costing over $670 per month 
as specialty tier products allowing to charge between 25 percent and 33 percent coinsurance for 
specialty tier drugs to enrollees. In addition, unlike commercial plans that cap members' out-of-
pocket drug spending annually, Medicare has no limit for prescription medications in Part D, its 
prescription drug benefit. 
As a result, Commercial patients may be shielded from cost-sharing initiatives, thus 
undermining Commercial insurers’ ability to influence generic drug utilization as may be found 
within Medicare and Medicaid beneficiaries. In addition, insurance providers with higher 
utilization uptake of generic glatiramer acetate occurs when initiatives to reduce prescribing 
costs drive use of MS generics by placing more restrictions on branded products compared to 








A literature review was conducted to expand on the background and unmet need for this 
study by analyzing previous research or available studies relating to my research question to assess 
any important findings to build on a theoretical foundation of knowledge and find applicable 
relevance in those insights. The primary objective of this literature review was to explore brand vs 
generic drug utilization trends in the treatment of multiple sclerosis and to gain an understanding 
on an optimal study design to approach research question. 
MS and Disease Modifying Therapies 
Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central 
nervous system (CNS) (Reich, Lucchinetti, & Calabresi, 2018). It is characterized by demyelination 
of axons (Figure 1) in the brain and spinal cord with axonal damage or destruction (English & Aloi, 
2015).  MS affects predominately patients aged 20-50 years with women affected twice as often as 
men (Gooch, Pracht, & Borenstein, 2017). The exact etiology is unknown and likely results from 
complex interactions of both environmental and genetic factors. The symptoms of MS vary 
depending in part on the location of lesions within the central nervous system. Common symptoms 
include sensory disturbances in the limbs, optic nerve dysfunction, pyramidal tract dysfunction, 
bladder or bowel dysfunction, sexual dysfunction, ataxia, and diplopia (Noyes & Weinstock-
Guttman, 2013). Although there is large variability in symptom manifestation and disease 
progression, MS is still the most common cause of non- traumatic disability in young adults and is 
associated with an average reduction in life span of 5 to 10 years (English & Aloi, 2015). Current 
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MS classification is based upon different defined clinical courses and consensus on the nature of 
the disease. The first is relapsing-remitting MS (RRMS), which is characterized by interspersed 
self-limited clinical events known as “relapses” or “attacks” of neurologic dysfunction with periods 
of clinical remission without disease progression in approximately 85% of patients (Weinshenker, 
1994). The second clinical course is secondary progressive MS (SPMS), which is comprised of 
about two-thirds of RRMS patients that progress in worsening neurological function due to 
accumulating axonal damage over years of active disease with or without attacks (Lublin, Reingold, 
& Cohen, et al).The third clinical type is primary progressive MS (PPMS), which is characterized 
by a continued steady decline in neurological function in about 10-15% patients from the first onset 
of a new attack or recurrent symptoms without any subsequent attacks (Koch, Kingwell, 
Rieckmann, & Tremlett). The fourth type is progressive–relapsing MS (PRMS), which also begins 
with a progressive course except patients do experience at least one occasional attack over a longer 
time period (Goodin, Frohman, & Garmany, et al, 2002). 
Figure 1: Axonal Damage Consequent to Demyelination. One of the potential mechanisms 
accountable for axonal loss following demyelination is Wallerian degeneration, whereby axons 
degenerate distal to the site of damage resulting in function loss or downstream effect including 
decreased levels of the neuronal marker N-acetyl aspartate (Lisak, 2007). 
 
 
There are no single clinical feature, laboratory test, or imaging findings that is enough to 
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diagnose that a person has MS. The diagnosis ultimately is a clinical decision based on weighing 
the factors that support the diagnosis against those that fail to support it or point to the possibility 
of an alternative diagnosis. The International Panel on MS Diagnosis criteria, also called the 
McDonald criteria, has set new diagnostic criteria for MS that incorporate the clinical characteristics 
and MRI features of CNS lesion “dissemination in space” (DIS – suggestions of damage in more 
than one place in the nervous system) and “dissemination in time” (DIT – suggestions that damage 
has occurred more than once) to speed the diagnostic process and reduce the chance of 
misdiagnosis thereby delaying treatment to limit permanent damage (Thompson, Banwell, & 
Barkhof, et al, 2018). 
Even though MS is not a curable disease, drug treatment options are available to reduce 
frequency of attacks, manage symptoms, and slowing down disease progression by targeting the 
mechanisms that underlie inflammation. The selection of MS drug treatment(s) has become very 
challenging because of the number and availability of therapies including new agents with more 
complex mechanisms of action and greater risks of adverse effects that may influence initial and 
subsequent therapeutic choice. Patients with MS may benefit from treatment but individual 
response to a given therapy and adverse events occurrence are largely unpredictable and many 
cases need to change several drugs to stabilize their disease. Although much remains unknown 
about the long-term effects of using or switching between disease-modifying therapies (DMTs), 
factors such as presence of co-morbidities, desire for pregnancy, previous use of other 
immunosuppressant’s, John Cunningham virus antibody seropositivity, geographical parameters, 
health insurance coverage, and patient/neurologist preferences can influence the treatment selection 
or sequence of treatment selection (Freedman, Selchen, Prat, & Giacomini, 2018). The choice of a 
specific agent should be individualized according to disease activity, patient values, and 
preferences. Currently, there are 17 DMTs approved by the U.S. Food and Drug Administration 
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(FDA) for the treatment of the various forms of MS as shown in Table 1. 
Table 1: FDA Approved Multiple Sclerosis Disease Modifying Therapies (adapted from 
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Recent studies have shown that early treatment with disease modifying therapies (DMTs) is 
associated with significant improvement in the patient’s quality of life (Kobelt, Lindgren, & Parkin, 
et al, 2000). In addition, MS medications can help achieve treatment goals by treating acute relapses, 
improve health-related QOL, reduce the frequency and severity of relapses, delay disability 
accumulation, and postpone the onset of the progressive phase of the disease (Phillips, 2004; 
Philips, 2009).  For example, when acute exacerbations occur (such as vision loss or loss of 
coordination), they are commonly treated with a short duration of high-dose oral or intravenous 
corticosteroid. If spasticity occurs, it can be addressed with muscle relaxants, however therapy with 
DMTs is designed to prevent relapses and progression of disability rather than treat specific 
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symptoms or exacerbations of the disease (Smith, Carson, & Fu, et al, 2010). These agents modify 
the immune response that occurs in MS through various anti-inflammatory, immunomodulatory or 
immunosuppressive effects. In 2018, the American Academy of Neurology (AAN) released new 
guidelines on the use of disease-modifying therapies (DMTs) in patients with MS to provide 
updated guidance on starting, switching, and stopping treatments including the recommendation 
for an earlier start to treatment rather than later in the disease course (Rae-Grant, Day, Marrie, et 
al, 2018). 
Glatiramer Acetate  
Among the DMTs available, glatiramer acetate stands out due to its unique mechanism of 
action, and excellent long-term efficacy/safety data. Glatiramer acetate (GA) is the generic name 
of a multiple sclerosis drug produced by Teva Pharmaceuticals and sold under the commercial or 
brand name Copaxone®. Copaxone® (glaterimer acetate) was the first of the currently approved 
DMTs to be tested in human subjects and is considered a standard choice for first-line treatment 
of RRMS. Copaxone® (glatiramer acetae) was approved by the FDA in 1996 began development 
at the Weizmann Institute in the 1960’s to study structural features of antigens involved in the 
induction of the animal model of MS (Varkony H, Weinstein V, Klinger E, et al., 2009). 
Glatiramer acetate is classified as a non-biological complex drug (NBCD) composed of a 
mixture of immunogenic polypeptides of varying amino acid sequences and sizes that are 
difficult to characterize even with state-of-the-art analytical methods (Weinstein, Schwartz, 
Grossman, 2015).  Glatiramer acetate is best described as a heterogeneous mixture of amino acid 
copolymers. Thus, glatiramer acetate is not a single molecular entity, but a distinct synthetic 
polypeptide comprised of varying lengths of interconnected peptide chains, some containing up 
to 200 amino acids with structural complexity comparable to that of proteins, or even more 
complex than proteins (Varkony, et al., 2009).  Glatiramer acetate is a manufactured amino acid 
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polymer of tyrosine, glutamate, alanine, and lysine analogous to biological products and thus is 
defined by its well-controlled manufacturing process. Glatiramer acetate resembles the myelin 
sheath components of myelin basic protein (MBP), which allows it to act as a decoy for immune 
targeting of myelin. Glatiramer acetate is administered by subcutaneous injection every day at 
the dose of 20 mg or alternatively three times a week at the 40 mg dose. 
The exact mechanism of action (MOA) of glatiramer acetate is unknown, but it is 
believed to function via a multifaceted affect involving both immunomodulation and 
neuroprotection (Figure 2). Its MOA is hypothesized to involve competition with myelin 
autoantigens at the major histocompatibility complex class II binding site on antigen-presenting 
cells, induction of antigen-specific Th2 T cells leading to bystander suppression of inflammation, 
and stimulation of neurotrophic factor secretion by immune cells (Schrempf & Ziemssen, 2007). 
Figure 2: Glatiramer Acetate Mechanism in Immune Modulation. The proposed mechanism 
of action relates to its immunologic effects such as the induction of antigen-specific suppressor T 
cells, inhibition of antigen presentation, displacing bound myelin basic protein (MBP), or causing 
an immune deviation in CD4_ T cells from a Th1 to a Th2 phenotype, which secrete anti-
inflammatory cytokines in the CNS through cross-recognition with myelin autoantigens through a 
series of distinct steps (Schrempf & Ziemssen, 2007). 
 
 
 Across five randomized controlled clinical trials, glatiramer acetate 20 mg has 
consistently demonstrated efficacy in reducing relapse rate and MRI disease activity and slowing 
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of disability progression in patients with RRMS, while possessing a favorable and well-
characterized safety record in both short and long-term studies (Boster, Ford, Neudorfer, & 
Gilgun-Sherki, 2015). Subsequently, the Glatiramer Acetate Low-Frequency Administration 
(GALA) study demonstrated the efficacy and safety of glatiramer acetate 40 mg 3 times a week 
in patients with RRMS (Khan, Rieckmann, Boyko, Selmaj, & Zivadonov, 2013). 
Injectable DMTs such as glatiramer acetate have dominated the MS market for over two 
decades, but the situation has changed because of the recent patent expirations of Teva’s 
Copaxone® (glatiramers acetate). This created an opportunity for approval of generics through the 
Abbreviated New Drug Application (ANDA) pathway established by the 1984 Hatch-Waxman 
Act (Mossinghoff, 1999), which permits FDA approval of applications to market generic versions 
of brand-name drugs without the need for costly and duplicative clinical trials. The FDA has made 
accelerated or expedited approval of less costly generic drugs a core objective in its mission 
designed to facilitate more generic competition, promote patient access, and improve the 
economics of developing generic medicines. Unlike the standard FDA drug-approval process that 
requires extensive preclinical (animal) and clinical (human) testing to establish safety and 
effectiveness (Van Norman, 2016), the approvals of generic drug products via the ANDA pathway 
do not generally require inclusion of preclinical and clinical data (Naziya, Sandeep, & Anoop, 
2018). Instead, physicochemical equivalence and bioequivalence to the innovator drug must be 
demonstrated scientifically to establish therapeutic equivalence (Chow, 2014). 
When an innovative (or brand-name) drug product is going off patent, pharmaceutical or 
generic companies may file an ANDA for generic approval, which in this scenario is for 
Copaxone®. Generic drug products are defined as drug products that are identical to an innovative 
(brand-name) drug which is based off an approved NDA with regards to active ingredient(s), route 
of administration, dosage form, strength, and conditions of use. Since ANDA submissions for 
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generic applications do not require lengthy clinical evaluation of the generic drugs under 
investigation (see Table 2), the price of a generic drugs is usually much lower than the cost of the 
originator brand. On average, generic entrants are about 30 - 60% of the price of the brand-name 
original (Zarowitz, 2008, Lewek & Kardas, 2010). As a result, increased use of less expensive 
generic drugs is encouraged as a means of healthcare savings and costs containment by policy 
makers, insurers, providers, and patients.  








7. Animal Studies 









NDA = New Drug Application; ANDA = Abbreviated New Drug Application 
 
In April 2015, the first generic version of the complex drug glatiramer acetate (Glatopa® 
20 mg/mL) injection was approved in the United States as a fully substitutable AP-rated generic 
for all approved indications of the 20 mg branded glatiramer acetate (Copaxone®) dosage form. 
Despite glatiramer acetate’s complex nature of being a chemically synthesized mixture of random 
peptide, the FDA approval occurred without conducting any clinical trials.  Subsequently, the 40 
mg Glatopa® formulation was approved in February 2018, while Mylan received FDA approval of 
both its generic formulations in October 2017. Teva contends that Copaxone® is too complex for 
another manufacturer to make an identical version of its drug, thus asserting that any new generic 
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version of Copaxone should be tested in clinical trials with MS patients to assure its safety and 
efficacy (FDA, 2015). Such a study has been conducted when the first phase III clinical trial to test 
a generic disease-modifying medication for multiple sclerosis treatment entitled the Glatiramer 
Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE), demonstrated that 
glatiramer acetate, the generic drug, was equivalent to the trademark drug Copaxone® for the 
treatment of MS (Cohen, Belova,, Selmaj, et al., 2015). Despite this clinical validation of generic 
sameness to the originator or reference listed drug (RLD), lingering healthcare stakeholder 
perceptions of this sameness versus potential difference concerns may remain a key influencer in 
potential treatment utilization. As a result, some stakeholders may perceive that generics as less 
expensive versions of the RLD, while others may believe that they are never fully identical to the 
RLD. 
Cost of Disease Modifying Therapies 
Spending on prescription drugs in the United States is on the rise and is projected to outpace 
growth in other parts of the healthcare sector in 2018 (Cuckler, 2017).  In addition, in 2017 there 
was a 14.6% increase in per member specialty drug spending, up from 10.1% the prior year. 
Consequently, it is project that by 2022, specialty drugs will account for a projected 47% of the 
pharmacy industry’s revenues. In 2017, four specialty classes accounted for over 75% of total 
expenditure for specialty drugs: (1) inflammatory conditions, (2) MS, (3) cancer, and (4) human 
immunodeficiency virus. Moreover, in recent years, the healthcare and managed care communities 
have witnessed a huge shift in expenditure from medical benefits towards pharmacy benefits, 
especially for newer oral agents that treat cancer or manage MS (Owens, 2013). Specialty drug 
spending now represents 46.5% of the net per-capital spending in the US. Of the $12 billion in net 
spending on new drugs, 75% was for specialty products exclusively (IQVIA, 2017). The IQVIA 
study also found that found the use of copay coupons in 42% of all specialty prescriptions compared 
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with 18% of all branded prescriptions filled through commercial plans. A contributing factor 
supporting high DMT costs and copay coupon use is the reality that most patients do not have to 
directly pay for their drugs. Copayments or out-of-pocket costs are meant to be paid by the patient, 
which should theoretically keep prices low. However, many pharmaceutical companies have 
counterattacked this by offering copayment coupons, which enable the company to pay some or all 
the patients’ costs while raising drug prices (Dafny, Ody, & Schmitt, M.A, 2016). For specialty 
conditions in which the initial cost of drugs is extremely high such as autoimmune diseases, hepatitis 
C, and multiple sclerosis coupon usage rates are greater than 50% (IQVIA, 2017). This high 
utilization of copay coupons is consistent with a study looking at the impact of patient copays or 
co-insurance on the probability of receiving disease-modifying therapies and on being adherent with 
treatment in patients with multiple sclerosis. The study confirmed that MS patients are sensitive to 
cost sharing by having a lower probability of receiving DMTs, lower probability of treatment 
adherence, and higher risk of treatment discontinuation (Palmer, Abouzaid, Shi, Fowler, Lenhart, 
Dastani, & Kim, 2012). Patients who are not adherent to their DMTs have higher risk of relapse, 
more emergency department visits and hospitalizations, and higher medical costs, thus reducing 
cost barriers may improve initiation of DMTs and treatment adherence. Specialty copayments or 
coinsurance is variable depending on the insurer but can range from as low as 20 percent or as high 
as 50 percent of the cost of the medication. MS patients covered by Medicare Part D plans where 
drugs costing $670 or more per month are placed on a “specialty tier,” may be subject to up to 33 
percent coinsurance making it potentially difficult for Medicare patients to afford their medications 
(Doshi, Ladage, Pettit, & Taylor, 2016). 
Despite the availability of more treatment options, costs for all MS DMTs have increased 
sharply in the United States (Sawad, Seoane-Vazquez, Rodriguez-Monguio, 2017). Between 2008 
and 2012, U.S DMTs sales doubled from $4 billion to nearly $9 billion annually (Hartung, 
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Bourdette, Ahmed, & Whitham, 2015). By 2013, first generation DMTs like IFNß-1b (Betaseron®) 
and glatiramer acetate (Copaxone®) grew to an average annual cost of over $60,000. Second 
generation DMTs (Oral agents) cost have increased from 8 % to 17 % annually since their approval. 
For example: fingolimod cost $50,775 in 2010 but has increased in cost by 8% to $63,806 by 2013. 
Similarly, with teriflunomide and dimethyl fumerate cost $47,651 and $57,816 respectively at 
approval but increased in cost by 17% ($57,553) for teriflunomide and by 14% ($63,315) for 
dimethyl fumerate (Hartung, Bourdette, Ahmed, & Whitham, 2015). Current annual wholesale 
acquisition costs of commonly used DMTs are shown in below in Figure 3. 
Figure 3: Commonly Prescribed MS DMT Annual Acquisition Cost (AnalySource, 2019)  
 
The high cost of MS DMTs in the United States is producing a cascade of negative effects 
upon patients with MS and their medical care. This can cause private insurers and public insurance 
regulatory bodies to require individuals with MS to meet specific criteria to obtain coverage for 
DMTs (Hohol, Orav, & Weiner, 1999) or require high copays (Minden, Frankel, Hadden, & 
Hoaglin, 2007). In what appears to be a direct response to the high cost of these drugs, insurance 
carriers have developed tiered formularies requiring step-wise DMT trials, with the tiers apparently 











of the various therapies (Miller, Happe, Meyer, & Spear, 2012; Owens, 2013). 
Overall, MS is a very costly chronic disease, with direct costs of prescription drugs and 
indirect costs being the most significant cost drivers, according to available data (Adelman, Rane, 
& Villa, 2013). The cost of providing health plan benefits and insurance coverage for MS therapy 
is one of the most rapidly growing segments of current healthcare expenditures. Evolving drug 
complexity portends increasing complexity for payers and health plans. Therefore, improved action 
plans must be developed that balance appropriate access to optimal therapies with the need to 
manage the high costs of DMTs and evolving treatments. Generic drugs are one of the most 
effective checks on rising drug costs in the United States (Kohl & Shrank, 2007). Today, about 9 
out of 10 prescriptions filled with simple, small molecule generic drugs. However, most MS DMTs 
are complex agents and not exposed to price competition from generics, except for the recent 
availability within the glatiramer acetate category. 
Healthcare Insurance Benefit Design 
 In the U.S., a health plan is an entity that provides or arranges for the insurance coverage 
of specific health services for an individual or group, either for a pre-determined price or by 
administering health benefits for entities like employers who opt to take on the financial risk 
themselves, often referred to as self-insuring (Morrisey, 2008). Today, health plans play a central 
role in the U.S. healthcare market by providing or administering health insurance as well as a 
range of services to its members on behalf of employers, individuals and government payers. As 
the country’s largest healthcare payer, the U.S. government has always influenced the benefit 
design of Medicare, Medicaid, Veterans Affairs and the Department of Defense (Brown & 
American Enterprise Institute for Public Policy Research, 2010). The U.S. government has 
increased its influence by setting standards for more affordable and simplified benefit structures 
that are reshaping traditional commercial health plan products thru bundled and value-based 
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payment reimbursement. 
In turn, private health plans must look for ways to control their expenses while 
maintaining enough quality to satisfy the needs of their clients and members. Pharmaceuticals, 
especially branded prescription drugs have been and will continue to be a top target for health 
plan cost control due to their high category growth and spend (Ballreich, Alexander, Socal, 
Karmarkar, & Anderson, 2017). However, health plans also know that pharmaceutical 
innovations create some of the greatest opportunities for better health and decreased overall 
costs. Government and private payers are trying to stabilize or reduce their healthcare spend by 
shifting more costs to consumers (Jencks, & Schieber, 1992). This is occurring across the market 
through higher deductibles, copays and premiums as well as greater use of coinsurance. It is most 
prominent in consumer-directed health plans (CDHPs) and the use of private exchanges, 
particularly for retirees. As consumers assume a higher share of healthcare costs, they face 
greater responsibility for healthcare choices and spending. 
Health plans typically organize their insurance services into three distinct areas of 
coverage based on the patient lives that they cover (Hoffman, Klees, Curtis, 2000):  
• Commercial: People under 65 may have access to what is often called group coverage as 
a benefit from their employer. If not covered under a group plan, the Affordable Care 
Act, (ACA) requires individuals to purchase coverage through a health plan exchange or 
face a penalty fee for remaining uninsured, but this is expected to end in 2019.  
• Medicare: People 65 and older, as well as permanently disabled individuals of any age, 
have access to Medicare a federally-funded insurance program. Medicare beneficiaries 
can choose to enroll in “traditional Medicare,” which is administered directly by the 
federal government, or enroll in Medicare Advantage with a private plan that administers 
the benefit on the government’s behalf.  
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• Medicaid: People of all ages who meet a low income threshold may have access to 
Medicaid a federally and state-funded insurance program. State governments may choose 
to administer their Medicaid program themselves or outsource it to a private plan, often 
referred to as a Managed Medicaid plan. 
Over two-thirds of the U.S. population is enrolled in a commercial market plan (Barnett, 
& Berchick, 2017). In addition, the U.S. Census Bureau shows 60 percent of Americans are 
covered through an employer, 16.2 percent purchase health insurance directly, and the rest are 
covered by Medicare (16.7 percent) or Medicaid (19.4 percent) or remain uninsured. Within this 
payer mix, MS patients receiving glatiramer acetate treatment regiments will find varying 
degrees of formulary coverage and benefit design relative to their insurer as shown in Figure 4. 
Figure 4: Insurer Benefit Design Coverage for Glatiramer Acetate Therapies (Managed 











































 Any private or public health plan that maintains a drug formulary irrespective of whether 
they contract or negotiate for product access will utilizes a Pharmacy and Therapeutics (P&T) 
Committee comprised of a medical director and/or prescribing physicians and the pharmacy 
director to assist in development and management of benefit design. P&T Committees may also 
include a nursing director or other allied care providers as well as a patient advocacy member 
representative of real-world clinical practice and community use. The committee is charged with 
developing and maintaining the drug formulary as well as analyzing new drug evaluations, new 
FDA approved indications for existing drugs, new clinical line extensions, and new published or 
clinical practice trends that may impact previous formulary placement decisions. Health plans 
increasingly include cost data as part of the P&T committee review process. In the absence of 
significant clinical differentiation, product formulary placement is likely to be financially 
oriented or incentive-based providing financial incentives (i.e., lower copayments) for enrollees 
to choose drugs that are preferred by the payer. 
To slow and even reverse healthcare spend especially for specialty pharmaceuticals, health plans 
have focused on specific pharmacy cost controls, including (Pharmaceutical Care Management 
Association, 2016):  
• Changes to benefit design that shift costs to consumers:  
• Increased premiums 
• Increased deductibles 
• Increasing co-pays, using co-insurance, including extending cost-sharing to drugs 
covered under the medical benefit, and increasing tier complexity.  
• Implementation of copay accumulator programs that enforces the patient’s full 
payment of the deductible without subsidization from the manufacturer’s copay 
program toward the cost of the drug.  
25  
• Access and utilization management tactics:  
• Employing approaches such as step therapy, prior authorization, the narrowing of 
formularies with limited brands to decrease use of high cost drugs, encourage use of 
lower cost options and generic utilization.  
• Implementing increasingly aggressive utilization management tools, including 
expanded use of formulary exclusions and introduction of new to market policies and 
NDC blocks.  
• Aggressively negotiating for price protection and rebates for preferred tier placement 
with drug manufacturers.  
 The need for pharmacy cost control and greater financial predictability is a key driving 
force behind pharmacy management tactics. Intense focus on specialty products have become a 
target. Plans have publicly stated their expectations on cost cutting by greater use of generics and 
biosimilars. Commercial, Medicare and Medicaid plans are increasingly challenged with 
controlling the costs associated with specialty medications. Active management of specialty 
drugs and the use of the best pharmacy go together in achieving great patient results with better 
savings. 
 Plans have always controlled pharmaceutical utilization through formulary management. 
However, the latest Utilization Management (UM) strategies particularly exclusion lists and 
New-to-Market Blocks are designed to address issues of higher product volume for non-preferred 
and/or high cost brands and pricing. These UM strategies continue to raise access hurdles and, in 
some cases, prohibit access. In a survey conducted by the National Disability Institute (NDI) and 
the Multiple Sclerosis Association of America (MSAA), results showed that access to health 
insurance is not a barrier for MS patients with only 7.7% uninsured and coverage consisting of 
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53.9% Commercial insurance and almost 39% received government funded healthcare, namely 
32.5% Medicare and 6.0% Medicaid (National Disability Institute, 2012). 
 An additional system for driving generic drugs in the United States is one of “switching” 
from a brand product to a generic equivalent (usually an AP or AB-rated generic in the Orange 
Book). Depending upon individual State Law requirements and insurer, substitution may be 
performed by a pharmacist for a prescription most often written as a brand name product and 
without specified preference (i.e. dispense as written) to a less expensive generic option if 
available with appropriate consent. One consequence of this system of substitution is that 
patients may have their medication “switched” either from brand to generic or from one generic 
to another generic without input from or knowledge of the physician or the patient without 
appropriate notification (Shrank, et al, 2010).  
Conclusion 
 
MS is an inflammatory and degenerative disease of the CNS affecting young adults. The 
burden of the disease in the society is very high representing the second cause of disability in 
young patients. In addition, MS is a very costly disease with a significant economic burden to the 
healthcare system. Given the prevalence of MS and increasing DMT utilization and costs 
associated with management of the disease, economic evaluation is important in making 
informed decisions. In a cost-conscious healthcare environment with ever growing fiscal 
responsibility being placed upon healthcare delivery, cost effective therapies like generic DMTs 
in MS are likely to become an important part of the decision- making process to use resources 
efficiently in the face of rapidly escalating costs of MS. 
This is an important area of research because of the very limited data analyzing the 
utilization uptake of generic glatiramer acetate post FDA approval using electronic prescription 
claims data. There currently are no large retrospective studies examining differences in generic 
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vs branded GA uptake in the MS prescription treatment category between payer types. Using 
prescription claims frequency or run rate trends, the investigators will create a linear regression to 
forecast future utilization of glatiramer acetate. Secondly, the investigators will compare patient 
out of pocket copayment costs between the three payer groups in addition to copayment card 








A retrospective, observational quantitative archival data analysis of Commercially 
insured, Medicare, and Medicaid prescription claims identified by 20 & 40 mg Copaxone®, 
Glatopa®, and Mylan glatiramer acetate national drug code utilization. 
 
Specification of Variables 
 
Glatiramer acetate (GA) use was identified by approved and dispensed pharmacy 
prescription fills in Commercial, Medicare, and Medicaid claims using national drug codes to 
compare ratio of branded versus generic GA prescription claim volume to total GA DMT 
prescription utilization. Glatiramer acetate prescription claims consisted of Copaxone®, Glatopa®, 
and Mylan Glatiramer Acetate prescription utilization over 52-months inclusive of FDA approved 
generic glatiramer acetate entrant timing within each of the three key insurance channels. In 
addition, patients’ out-of-pocket copayment amounts for specific drugs were compared between 
payer groups, as well as manufacturer prescription copayment coupon or foundational assistance 




Symphony Health – Integrated Dataverse® data set from October 1, 2014 – January 31, 
2019 licensed to Pfizer Inc. in connection to statement of work in de-identified format in 
compliance with the Health Insurance Portability and Accountability Act of 1996 and its 
implementing regulations (“HIPAA”). Symphony Health – Integrated Dataverse® de-identified 
claims data set fields available for analysis are shown in Table 3 of the Appendix.  
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Data Set Construction 
 
1. Monthly prescription claims for Copaxone®, Glatopa® and Mylan Glatiramer Acetate 
(numerators). Specific National Drug Code (NDC) numbers included in the data set: 
• Copaxone®: 06854631730 (20 mg 30 Pre-filled Glass Syringe Blister Pack in 1 Carton) 
and 06854632512 (40 mg 12 Pre-filled Glass Syringe Blister Pack in 1 Carton) 
• Glatopa®: 00781323434 (20 mg 30 Pre-filled Glass Syringe Blister Pack in 1 Carton) 
and 00781325089 (40 mg 12 Pre-filled Glass Syringe Blister Pack in 1 Carton) 
• Mylan Glatiramer Acetate: 00378696093 (20 mg 30 Pre-filled Glass Syringe Blister 
Pack in 1 Carton) and 00378696112 (40 mg 12 Pre-filled Glass Syringe Blister Pack in 1 
Carton) 
2. October 1, 2014 – January 31, 2019 total FDA approved glatiramer acetate DMT claims 
(denominator). 
  
3. Prescription claim coverage and transactional specifics for Copaxone®, Glatopa® and Mylan 
Glatiramer Acetate including utilization of out-of-pocket support in the form of copay or 




1. Calculated monthly uptake of each glatiramer acetate (GA) by insurance payer 
(Commercial, Medicare, and Medicaid) by comparing prescription claim volume of 
utilization to total GA DMT utilization. The claims ratio is used to construct three 
different growth curves showing the uptake trends for each version of glatiramer 
acetate. 
• A future growth curve of branded and generic utilization was constructed based on 
percentage increases and compared to previous period to forecast projected 
utilization based upon regression analysis for the remainder of 2019 insurer benefit 
cycle. 
 
2. Mean monthly dollar value of patient out-of-pocket costs compared between 
Commercial, Medicare and Medicaid insurance groups for each glatiramer acetate 
medication. 
• Percentage of claims with manufacturer or foundational copay assistance per insurer 
type. 
 
• Commercial insurance: Percent of claims that have utilized manufacturer 
copayment cards. 
• Medicare: Percent of claims with free or reduced cost prescription offers for 
those qualifying either for patient assistance programs or those eligible for 
Medicare “extra help” assistance. 
• Medicaid: Percent of claims with zero cost or prescription patient assistance as 
a low-income subsidy. 
Institutional Review Board 
 
Symphony Health Integrated Dataverse® claims data set licensed by Pfizer Inc. is de-
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identified and qualifies as non-human research as set forth by the guidelines of the MUSC 




A review of the literature on brand vs generic glatiramer acetate utilization in the 
management of relapsing remitting multiple sclerosis reveals a lack of comprehensive 
theoretical framework for understanding these events and their complexities. Applying a 
process of conceptual framework analysis, as shown in Figure 5, will provide a theoretical 
framework to shed new light on the feasibility of implementing sustainable generic 
prescribing practices. This study will contribute important informational insights on MS 
brand vs generic utilization and help provide additional context to possible influences in 
generic drug prescribing or switching. 
Figure 5: Project Conceptualization Chart: A conceptual diagram outlining the study 
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Please find enclosed our manuscript submission entitled: “Prescription Trends in Branded 
Versus Generic Glatiramer Acetate Utilization Among Insurers for the Treatment of Multiple 
Sclerosis in the United States.” The study provides insight on current trends in generic glatiramer 
acetate (GA) utilization across various payment channels based upon recent availability. The 
utilization of lower cost generics over branded offering could result in healthcare savings. 
Rising healthcare spend on multiple sclerosis (MS) drugs raises the question of what role 
does a generic glatiramer acetate have within MS treatment or acceptance by stakeholders. 
Notably, no study has specifically evaluated the differences in utilization uptake of branded vs 
generic GA among the major insurer categories. The purpose of this study is to establish whether 
insurer type affects the rate of utilization uptake of branded vs generic GA. 
To address this research gap, we extracted glatiramer acetate prescription records from 
Symphony Health Integrated Dataverse® archival billing data for patients covered by 
Commercial, Medicare, and Medicaid for 52 months from Oct. 2014 – Jan. 2019. Our analysis 
of glatiramer acetate claim rates revealed a substantially lower utilization of generic glatiramer 
acetate across all payer types compared to the brand. The greatest increases in generic were 
observed in Commercial and Medicare patients. The results indicate a significant brand 
preference with low payer management directing glatiramer acetate prescriptions toward the 
generic options. 
Thank you for considering our manuscript for publication. We appreciate your time and 
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BACKGROUND: Glatiramer acetate has been a core component of disease modifying therapy 
for multiple sclerosis since its introduction in 1996. However, branded glatiramer acetate has 
increased in acquisition cost by approximately 1000% to approximately $90,000 per year. 
Because of the drug’s high cost and availability of alternative lower cost generic options, insurers 
may use various strategies to control branded utilization, while encouraging generic alternative 
use. 
OBJECTIVE: To observe and report variances of generic vs branded glatiramer acetate 
utilization by insurance type. 
METHODS: Final approved nationwide pharmacy transactional claims for Copaxone®, 
Glatopa®, and Mylan Glatiramer Acetate were extracted from Symphony Health Integrated 
Dataverse® data set from October 1, 2014 – January 31, 2019 for Commercially insured, 
Medicare beneficiaries with supplemental insurance, and Medicaid patients. Branded versus 
generic glatiramer utilization rates were calculated based upon volume and using simple percent 
change projection and regression modeling. Patient out-of-pocket costs and prescription 
assistance were categorized by insurance payment type. 
RESULTS: Over the 52-month period, 111,906 patients with multiple sclerosis were prescribed 
glatiramer acetate by Neurologists (80%) and had 1,624,159 approved dispensed claims 
primarily through specialty mail (87%) and categorized by payment type as 63.2% Commercial, 
25.4% Medicare, and 11.8% Medicaid. The market trend showed a consistent decline in 
branded glatiramer acetate claims offset by increasing uptake in generic glatiramer acetate with 
the launch of additional generic market entrants. Generic market share has continued to grow 
reaching an approximate 30% share of claims. Branded glatiramer acetate utilization has 
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declined by more than 56%, while generic claim volume has grown 155% over the past 16 
months. Among the payer types, Medicare has observed the greatest brand decline at 70% and 
the second highest generic utilization. Commercial insurers have the greatest category claim 
volume and greatest generic growth to a 26% share, while the brand has declined by 44%. 
Medicaid has had the lowest utilization volume and the greatest ratio of generic utilization 
among insurers at 45%. Patient out of pocket costs are highest with branded use across all 
insurer types, while Medicaid has the lowest patient out-of-pocket costs.  
CONCLUSIONS: The study revealed that generic glatiramer acetate adoption or utilization 
has been slow among insurers but increasing over the past sixteen months with additional 
generic glatiramer acetate entrants and increased price competition. The greatest trend in 
generic utilization is occurring within the Commercial channel followed by Medicare and then 
Medicaid, which has had the lowest growth trend. The results indicate that barriers to generic 
glatiramer acetate may vary by insurer and influenced by prescriber or patient choice. Generic 
uptake is projected to increase across all insurer types reflective of trends during 2019 open 
enrollment and healthcare benefit design change associated with a new health insurance cycle. 
 
SUMMARY BULLETS 
What is already known about this subject 
• Glatiramer acetate is a structurally complex, nonbiologic, established as an 
effective treatment for multiple sclerosis with a well-recognized safety and 
tolerable profile 
• Branded multiple sclerosis drugs have high yearly costs adding to high long-term pharmacy 
costs. 
• Strategies to decrease healthcare costs include increasing the use of generic drugs through 
brand-name drug utilization management. 
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What this study adds 
• Examines differences in utilization rates by payer type for branded versus generic 
glatiramer acetate over the past 52 months. 
• Forecasts future utilization of generic glatiramer acetate options relative to brand. 




Multiple sclerosis (MS) is a common neurologic disease affecting more than 1 million 
people in the United States.1 The etiology is assumed to be an autoimmune process leading to an 
inflammatory condition that damages the myelin of the central nervous system and causes 
progressive neurologic impairment and frequently severe disability.2 
In the absence of a cure, MS therapy consists primarily of supportive care and symptomatic 
management, which may generate substantial direct costs. Management of multiple sclerosis has 
evolved in recent years, due in part to the availability of first generation and newer disease 
modifying therapies (DMT) that are immunomodulating with improving efficacy, convenience, and 
higher associated cost.3,4  However, these newer DMT’s with improved clinical benefits are often 
associated with adverse events (AEs) that are uncommon, but significant, such as progressive 
multifocal leukoencephalopathy (PML) or cardiac arrhythmias.5 Glatiramer acetate is the most 
frequently prescribed DMT for MS, with an efficacy, safety, and tolerability profile backed by over 
two decades of real-world and clinical data.6 
Teva’s glatiramer acetate (Copaxone®) is a first generation DMT approved in 1996 to treat 
multiple sclerosis. It has quickly proved effective, popular and a mainstay of first line treatment 
among healthcare professionals and patients, gaining a reputation for turning multiple sclerosis into 
a manageable chronic disease.7 ,8  Glatiramer acetate is considered a high-cost specialty drug. 
Specialty drugs are typically high price products used to treat rare, complex conditions with 
characteristics that may impede generic substitution or interchangeability.8 Branded glatiramer 
acetate (Copaxone®) has increased in price by 1000 percent and now costs approximately $7,000 
per month/$88,000 per year.1 0  
Payers encourage the use of generic drugs to lower total drug spending with generic drugs 
representing 89% of all prescriptions.11 This can be achieved by increasing management utilization 
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of branded drugs such as prior authorization or step therapy, leveraging mandatory generic auto-
substitution pharmacy switches or offering lower patient copayment on generic drugs.12  Generic 
price competition has historically been a successful strategy for lowering prescription drug prices 
in the United States.13 Specialty drugs, including injectables and generics may be an exception due 
their use in complex situations like critical care, cancer, and autoimmune disease due to higher 
escalating price increases that drive up cost.14 In addition, pharmaceutical manufacturers differ in 
how they approach their pricing strategies, both for a new generic launch or for the defense of a 
brand name drug. As a result, the presence of pre-existing or re-negotiated contracts may create 
financial incentives (spread compensation) for a payer to stay with the branded drug for a longer 
time, rather than automatically switch to the new generic without the appropriate financial 
incentives15. 
In April of 2015, the FDA approved the first fully AP substitutable generic version of the 
glatiramer acetate called Glatopa in the United States.16 As the first U.S. generic manufacturer of 
glatiramer acetate, Sandoz/Momenta launched the 20 mg generic formulation in June 2015 at a 
15% discount to the wholesale acquisition (WAC) price of the brand-name Copaxone.17 In October 
2017, Mylan received Food and Drug Administration (FDA) approval of a second 20 mg generic 
version and the first 40 mg generic version of Teva’s multiple sclerosis medicine Copaxone 
including pricing both at a 30% discount.18 Subsequently, Sandoz/Momenta received approval on a 
40 mg generic version of Teva’s Copaxone in February 2018 matching the Mylan market pricing 
approach.19 In June 2018, Mylan further reduced their WAC price discount compared to Teva’s 
Copaxone by approximately 66% or a flat $1,950 per month acquisition cost.20 As a result, Teva 
and Sandoz are likely to offer additional discounts or rebates to customers in an attempt match 
Mylan’s pricing out of competitive pressure in order avoid losing formulary status or market share. 
Whether these negotiated discounts or rebates will be passed on to patients at pharmacy point of 
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sale points or withheld for insurer/pharmacy benefit manager profit remains to be determined. 
Little is known about glatiramer acetate utilization in the treatment of patients with 
multiple sclerosis among insurers after expiration of market exclusivity for the brand-name 
medication (Copaxone®). In this study, we aim to examine trends in utilization and 




We conducted a retrospective analysis of de-identified prescription pharmacy claims and 
eligibility data extracted for the period October 1, 2014 – January 31, 2019 using Symphony Health 
Integrated Dataverse® claims data identifying Copaxone®, Glatopa®, and Mylan Glatiramer Acetate 
National Drug Code (NDC) numbers using final approved and dispensed prescription fills in 
patients with multiple sclerosis. To compare different formulation quantities of medication, fills 
were standardized to represent a single month’s glatiramer acetate supply (30 day) for the 
recommended dose for relapsing remitting multiple sclerosis (20 mg/day and 40 mg three times a 
week) and aggregated.  
Our primary aim was to understand shifts or trends in treatment usage from brand to generic 
glatiramer acetate agents over the study period. We calculated the market share of glatiramer 
acetate drugs over time among the generic option relative to brand for therapy. Uptake of generic 
glatiramer acetate was estimated as the percentage of all glatiramer acetate fills for which the 
generic product was dispensed relative to brand. Two forecasting growth charts were constructed to 
predict future uptake growth for glatiramer acetate within the Commercial, Medicare, and 
Medicaid insurance groups. Branded and generic growth is calculated using a fixed percentage 
change each month based on the observed rate each monthly period from October 2014 to January 
2019, plus projected another 11 months for the brand.  
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Secondary analyses compared the mean monthly patient out of pocket costs across the three 
payment types. In addition, we examined the percentage of claims receiving prescription assistance 
either from a manufacturer copayment program or foundational assistance that effectively reduces 
or zero’s patient out-of-pocket expense. 
The study was exempt from institutional review board review, as only a limited dataset was 
accessed in full compliance with the Health Insurance Portability and Accountability Act of 1996. 
RESULTS 
 
From October 2014 to January 2019, 111,906 patients with multiple sclerosis were 
prescribed glatiramer acetate. As shown in Table 1, patient demographics were consistent with 
disease epidemiology. Most patients were female (77%) between the age of 31 – 60 (67%) with 
a similar geographic distribution.  Primary insurance coverage was 63.2% Commercial, 25.4% 
Medicare, and 11.8% Medicaid. The primary prescriber of glatiramer acetate is a Neurologists 
(80%) and the vast majority of the 1,624,159 approved claims dispensed were through a 
specialty mail order pharmacy (87%).  
Figure 1 shows the market trend of a consistent branded glatiramer acetate claim decline 
offset by a rapid uptake in generic glatiramer acetate (Glatopa® 20 mg) with its initial market 
entry and then remaining flat until launch of next generic entrant (Mylan 20/40 mg GA). 
Generic market share has continued to grow reaching an approximate 30% share of claims as of 
January 2019. Over the 52 months brand glatiramer acetate utilization has declined more than 
half at 56%, while generic claim volume has grown 155% over the past 16 months.  
Figure 2 shows the relative claim volume by payment type for comparison. Among the 
payer types, Medicare has observed the greatest brand decline at 70% and the second highest 
generic utilization uptake at a 28% share. Commercial insurers have the greatest category claim 
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volume and greatest generic growth to a 26% share, while the brand has declined by 44%. 
Medicaid has had the lowest utilization volume and the greatest ratio of generic utilization among 
insurers at 45%. 
Figure 3 shows projected or forecast branded utilization decline is greatest within the public 
insurance channel (Medicaid & Medicare). Medicare has the greatest forecast decline in brand 
utilization. Figure 4 reflects the projected generic utilization rate being greatest within the 
Commercial channel, while lowest in Medicaid. 
Table 2 compares mean monthly patient out-of-pocket (OOP) costs for glatiramer acetate 
versions between Commercial, Medicare, and Medicaid insurers. Medicare has the highest patient 
cost share among insurers with both branded and generic glatiramer acetate having the highest 
mean OOP cost ($403 vs $330). Lower mean patient out-of-pocket costs are generally observed 
with generic glatiramer acetate options based upon monthly medication fulfilment. Medicaid has 
the lowest cost share among the three insurer types. Across all payment types, generics offer 
approximately a 20% discount to the brand in patient out of pocket costs. Manufacturer copay 
coupon or foundational assistance is also provided for both brand and generic glatiramer acetate to 
assist with patient affordability. A greater degree or percent of assistance for $0 patient pay is 
observed within Medicaid, while Medicare patients also have benefited from foundational assistance 




Switching branded to generic medications has been a common cost containment measure 
among insurers.21 Brand to generic switching is also common place across many therapeutic areas. 
In this retrospective, observational study of brand versus generic glatiramer acetate (GA) utilization 
among various insure types over 52 months, we found that generic utilization is occurring, but at a 
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much slower rate and still evolving among insurers. In our analysis there is still a disproportionally 
greater utilization of branded GA versus the generic glatiramer acetate across all insurer types, 
although it is declining over time. This preference for the brand may reflect historical brand loyalty 
or a lack of provider, patient, or insurer incentive to change to the generic unless by choice or 
select insurer mandate.22 The decline in branded glatiramer acetate does not appear to be offset by 
the degree of increasing generic utilization, so it may be indicative that patients may be switching 
to other branded DMT therapies. In addition, standard generic switch models of brand conversion 
rely on mandatory generic auto-substitution by pharmacists, which does not appear to be 
occurring.23 However, increasing generic utilization over the past 16 months has improved 
dramatically with the additional generic introduction of Mylan’s glatiramer acetate at its significant 
discounted list price. The overall increased market utilization of generic glatiramer acetate appears 
to be consistent across insurers and the utilization trend appears to be continuing through at least 
the first month of the new 2019 benefit cycle. This may be indicative of changes in benefit design 
or formulary administration favoring greater preferred generics utilization that assists in controlling 
drug costs benefiting insurers, providers, and patients. 
Healthcare benefit policies are continuously adjusted to improve value relative to quality 
healthcare delivery.24 This can result in more costs being shifted to the beneficiaries, raising issues 
in affordability especially for the high cost specialty pharmacy category multiple sclerosis disease 
modifying therapies. These cost shifts can include higher yearly premium increases, rising 
deductible limits or implementation of copay accumulator programs, greater utilization of 
coinsurance requiring beneficiaries to pay a greater percentage of the full cost of a drug, and 
benefit design changes that may eliminate coverage of a drug or move a drug from a lower price 
tier to a higher one including generic drugs normally on the less expensive tier 1 or 2, to the much 
more expensive 4th or 5th specialty tiers.25 This effectively eliminates any preferred drug advantage 
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between a generic vs brand option in a category like specialty multiple sclerosis drugs and requires 
patients to share a higher cost of these medications. It forces patients to pay increased out-of-
pocket (OOP) costs for important specialty drugs that likely have no medically comparable 
alternatives for treating a serious condition cost effectively.26 Patient OOP’s are a key lever in 
product decision making and selection as many insurance beneficiaries are on fixed incomes such 
as retired or disabled Medicare patients, low income/uninsured Medicaid participants, or even 
middle class Commercial lives with low annual per capita incomes where high out-of-pocket health 
care costs can pose a challenge in those with significant medical needs that are having to pay more 
for healthcare delivery. Thus, the use of lower cost generic drugs would seem to make more sense 
from a patient affordability or economic perspective.  
Economics or financial incentives may also be a key influencer in insurer decision 
regarding preferred brand or generic utilization.27 Insurers may be motivated to shift financial risk 
exposure to the patient or improve internal operating margins. This influence can create misaligned 
incentives whereby insurers or their pharmacy benefit managers (PBM) structure benefit design 
based on self-benefiting financial profit motives relative to manufacturer negotiated preferred 
product formulary tier positions that lead to greater retained rebates and discounts paid for insurers.  
In theory, these discounts or formulary structures should benefit patient product access or 
affordability directly at a pharmacy point of sale where a prescription is dispensed leading to both 
lower patient OOP’s and pharmacy drug costs. Unfortunately, most patients pay their out-of-pocket 
costs based on the list price of the drug, not on the discounted price given by the drug company. As 
a result, insurers may have incentives to continue using an expensive specialty branded drug like 
Copaxone® instead of a generic simply based upon the economics. To address both high costs and 
access restrictions to all available multiple sclerosis treatments, greater transparency and financial 
disclosures between policy makers, insures, and pharmaceutical companies are required. However, 
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for commercial patients, high out-of-pocket cost shifts can also be addressed by drug manufactures 
in the form of copay assistance cards that manufacturers provide to patients in order increase the 
utilization of branded drugs despite the cost. These copay coupons or vouchers work by paying the 
patient’s required portion of payment and could also explain why branded glatiramer acetate is 
used disproportionately to the generic.  
Public insurers like Medicare, created to increase access to prescription drug treatment 
among beneficiaries, may also shift costs of specialty drugs to beneficiaries. Medicare plans, which 
are administered by the same Commercial insurers and PBMs can charge between 25% and 33% 
coinsurance for specialty tier drugs before enrollees reach the coverage gap or “doughnut hole” 
where they have paid anywhere for 25-45% of the cost of their drugs. Once their total out-of-
pocket spending exceeds an annual threshold of $5,100 in 2019, enrollees pay 5% of the total drug 
costs above the catastrophic coverage threshold.28 As a result, Medicare beneficiaries may pay 
more for the brand in theory, but secondary insurance obtained as part of a retirement benefit or 
prescription assistance programs from foundations can cover or offset the higher monthly cost of 
using a brand. This would explain why brand utilization is still dominate in our study. The 
importance of secondary assistance is captured in our data analysis by the observation of a 
significant drop in brand utilization in second quarter 2016, when the Department of Health and 
Human Services Office of Inspector General (OIG) issued an OIG Advisory opinion stating that 
charity prescription assistance programs (PAP) cannot be supported through drug manufacturer 
donor (or its affiliate) contributions that exerts any direct or indirect influence or control over the 
PAP due to perceived violation of Anti-Kickback Statutes. The elimination of donations by 
manufacturers and the closure of PAP charities resulted in a decrease in secondary assistance 
available to help pay for the higher costing brand. As a result, the beneficiary cost shift not only 
helps explain the dramatic drop in brand utilization but also may explain the more recent increase 
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in generic utilization simply based upon affordability for some patients. Medicare patient out-of-
pocket costs in general for specialty products are higher for the brand compared to a less expensive 
generic alternative.  
In our analysis, Medicaid had the lowest utilization of either brand or generic GA compared 
to either Commercial or Medicare payment types. As stated previously, Medicaid provides health 
coverage for some low-income and uninsured individuals or nonelderly adults that are the least 
likely to be able to afford expensive specialty drugs. Oversight by the Department of Health and 
Human Services requires states to provide drugs to Medicaid beneficiaries without excluding even 
these high cost specialty therapies. However, Medicaid pays some of the lowest costs for 
pharmaceuticals as Medicaid plans receive supplemental rebates from manufacturers to lower 
government spending on prescription drugs. This allows states to create a preferred drug list 
encouraging physician to only prescribe therapies on that list, which are often more affordable and 
have the greatest negotiated supplemental rebates provided by manufacturers. Although prior 
authorization normally is utilized to manage high cost drugs by encouraging generics or excluding 
non-preferred tier drugs, states are almost always required to provide access to drugs from 
manufacturers that have signed a rebate agreement with the state. This allows brand manufacturers 
to not only compete on price with generics, but also gain preferred coverage status and higher 
potential utilization as seen in our analysis. Even with healthcare reform expanding Medicaid 
eligibility in many states thereby improving access to MS treatments, the high cost of MS DMTs 
can still be prohibitive even if supported by prescription assistance programs that may even assist 
in covering costs of high risk insurance plans or even elderly patients Medicare premiums if 
eligible. 
Considering generic glatiramer has been availability since 2015, decreased usage may 
reflect delayed formulary inclusion because of benefit design negotiations cycles or insufficient 
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stakeholder motivation for action either from an economic, clinical, or behavioral perspective. 
Despite obvious lower list prices with generics and the potential impact of direct multiple sclerosis 
pharmacy cost reductions and patient OOPs, some stakeholders may harbor clinical reservations or 
concerns about using these newer generic options in an immune mediated condition without more 
patient exposure experience or until insurer incentives are employed that mandate generic first use 
or incentivize pharmacy mediated auto-substitution. Either should be achieved through an aligned 
process of strong insurer incentives to drive generic utilization via standard benefit design and 
formulary management, improved communication between payers, physicians, pharmacists, and 
patients on generic advantage to decrease healthcare costs, and educational initiatives to improve 
confidence and trust in generic use in multiple sclerosis as a safe and effective alternative to the 
brand. It is critical to effectively manage patient outcomes and associated costs by selecting and 
using the most cost-effective drugs for formulary inclusion with the appropriate utilization 
management incentives to drive usage. 
The strength of this study is our ability to report changes in utilization patterns of brand 
versus generic glatiramer acetate over 52 months inclusive of two generic entrants. However, 
several limitations are warranted for consideration. First, this claims data set does not identify 
intent of medication prescribing or usage by either physician or patient. Improved data reporting 
and analysis could be improved by factoring prescriber/patient longitudinal information to more 
accurately show insights on claim trends and volume. Second, the Symphony Health Integrated 
Dataverse® claims data set is a blend of captured adjudicated pharmacy life cycle claims (43%), 
final pharmacy non-life cycle claims that are only report final transactional status (51%), and a small 
proportion of medical benefit claims (6%). As a result, not all data sets or fields are available thus 





The purpose of this study was to examine whether insurance type affected the rate of 
utilization uptake of generic glatiramer acetate over 52 months inclusive of FDA approval of these 
new low-cost options for multiple sclerosis treatment. The study revealed that utilization of generic 
glatiramer acetate has been limited among insurers but has been increasing over the past sixteen 
months as more generic GA options are available and price competition increases. Generic uptake 
is projected to increase across all insurer types. A recent increase in generic utilization over the past 
five months is indicative of a changing benefit design and reflective of 2019 open enrollment and 
in anticipation/execution of a new health insurance coverage cycle. Lower patient out-of-pocket 
costs and generic preferred formulary positioning will drive uptake rates for those with the greatest 
cost shift risk. Patients in our analysis had higher out-of-pocket costs when using the brand versus 
the generic option. 
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Table 1: Baseline descriptors of pharmacy claims data set for  
glatiramer acetate from October 2014 through January 2019  
Patient Characteristics (n=111,906) n % 
Sex   
     Female 86,283 77.10 
     Male 25,500 22.79 
     Other 123 0.11 
   
Age Distribution   
     0 - 10 18 0.02 
     11 - 20 627 0.56 
     21 - 30 6,085 5.44 
     31 - 40 18,128 16.20 
     41 - 50 25,981 23.22 
     51 - 60 31,099 27.79 
     61 - 70 22,998 20.55 
     71 - 80 6,968 6.23 
     Unknown 2 0.00 
   
Payer Type   
     Commercial/other 70,725 63.20 
     Medicare 28,442 25.42 
     Medicaid 12,739 11.38 
   
Geographic Region   
     Northeast 26,237 23.45 
     Midwest 27,010 24.14 
     South 36,124 32.28 
     West 21,494 19.21 
     Other 1041 0.93 
   
Claim Characteristic (n=1,624,159) n % 
Pharmacy Type   
     Mail Order 1,408,597 86.73 
     Retail 140,636 8.66 
     Non-retail 65,434 4.03 
     Specialty 9,492 0.58 
   
Physician Specialty   
     Neurology 1,290,990 79.49 
     Neurophysiology, Clinical 73,198 4.51 
     Family Practice 63,385 3.90 
     Family Medicine 55,459 3.41 
     Internal Medicine 34,263 2.11 
     Other 106,864 6.57 
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Figure 1: Over the course of 52 months branded glatiramer acetate has been declining, while 
generic utilization has increase based upon new market entrant launches and market price 
adjustments.  Branded glatiramer acetate utilization has declined 56%, while generic claim 
volume has grown 155% over the past 16 months. The decline in branded utilization may be 




















Figure 2: Bar chart depiction of monthly brand versus generic glatiramer acetate claim volume by 
primary insurer type. Commercially insured accounts for the greatest volume of both brand and 















































































































































Sum of Glatiramer Acetate Claims by Payer
52  
Figure 3: Trends in brand and generic glatiramer acetate utilization from October 2014 – January 
2019 including projection through the next eleven months to December 2019. The projected 
percent change decline in brand use is lowest within the Medicare channel, while greatest in 
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Table 2: Table comparing mean monthly patient out-of-pocket (OOP) costs between 
Commercial, Medicare, and Medicaid insurers. Greatest patient cost share is associated with 
branded glatiramer acetate use and highest within the Medicare channel where higher 
coinsurance is predominant. Lower patient out-of-pocket costs are observed with generic 
glatiramer acetate options based upon monthly medication fulfilment. Medicaid has the lowest 
cost share among the three insurer types, but also has the largest proportions of patients receiving 
prescription assistance. All insurer types have a proportion of patients receiving prescription 
assistance. 
 









Copaxone 13% $300 $0 $9,279 
Glatopa 43% $201 $0 $6,988 
Mylan GA 23% $224 $0 $6,988 
Medicare 
Copaxone 21% $403 $0 $9,273 
Glatopa 38% $339 $0 $3,900 
Mylan GA 32% $317 $0 $3,986 
Medicaid 
 
Copaxone 34% $80 $0 $7,003 
Glatopa 45% $3 $0 $1845 
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Table 3: Symphony Health -Integrated Dataverse® True Benefit Design de-identified claims data 
set fields licensed by Pfizer Inc. 
 
ColumnName ColID DataType 
PATIENT_ID 1 VARCHAR2 (20 Byte) 
CLUSTER_ID 2 VARCHAR2 (61 Byte) 
RX_ORDER 3 NUMBER 
YEAR_MONTH 4 VARCHAR2 (6 Byte)  'YYYYMM' 
FLAG_LIFE 5 VARCHAR2 (14 Byte) 
PHARMACY_TYPE 6 VARCHAR2 (30 Byte) 
PATIENT_AGE_GRP 7 VARCHAR2 (7 Byte) 
PATIENT_GENDER 8 VARCHAR2 (6 Byte) 
INITIAL_PRODUCT 9 VARCHAR2 (60 Byte) 
INITIAL_DRUG 10 VARCHAR2 (60 Byte) 
INITIAL_GENERIC 11 VARCHAR2 (60 Byte) 
INITIAL_BRAND_GENERIC_IND 12 CHAR (1 Byte) 
INITIAL_PRODUCT_STRENGTH 13 VARCHAR2 (10 Byte) 
INITIAL_DRUG_QTY 14 NUMBER 
INITIAL_PRODUCT_FORM 15 VARCHAR2 (40 Byte) 
INITIAL_NDC 16 CHAR (11 Byte) 
INITIAL_DAYS_SUPPLY_GROUP 17 VARCHAR2 (7 Byte) 
INTERIM_PRODUCT 18 VARCHAR2 (60 Byte) 
INTERIM_DRUG 19 VARCHAR2 (60 Byte) 
INTERIM_GENERIC 20 VARCHAR2 (60 Byte) 
INTERIM_BRAND_GENERIC_IND 21 CHAR (1 Byte) 
INTERIM_PRODUCT_STRENGTH 22 VARCHAR2 (10 Byte) 
INTERIM_DRUG_QTY 23 NUMBER 
INTERIM_PRODUCT_FORM 24 VARCHAR2 (40 Byte) 
INTERIM_NDC 25 CHAR (11 Byte) 
INTERIM_DAYS_SUPPLY_GROUP 26 VARCHAR2 (7 Byte) 
FINAL_PRODUCT 27 VARCHAR2 (60 Byte) 
FINAL_DRUG 28 VARCHAR2 (60 Byte) 
FINAL_GENERIC 29 VARCHAR2 (60 Byte) 
FINAL_BRAND_GENERIC_IND 30 CHAR (1 Byte) 
FINAL_PRODUCT_STRENGTH 31 VARCHAR2 (10 Byte) 
FINAL_DRUG_QTY 32 NUMBER 
FINAL_PRODUCT_FORM 33 VARCHAR2 (40 Byte) 
FINAL_NDC 34 CHAR (11 Byte) 
FINAL_DAYS_SUPPLY_GROUP 35 VARCHAR2 (7 Byte) 
SUBSTITUTION_FLAG 36 CHAR (1 Byte) 
MULTI_PAYER_FLAG 37 CHAR (1 Byte) 
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COPAY_CARD_FLAG 38 CHAR (1 Byte) 
INITIAL_PAYMENT_TYPE 39 VARCHAR2 (10 Byte) 
INITIAL_BADMIN_NAME 40 VARCHAR2 (250 Byte) 
INITIAL_MCO_NAME 41 VARCHAR2 (250 Byte) 
INITIAL_PLAN_NAME 42 VARCHAR2 (250 Byte) 
INITIAL_PLAN_TYPE 43 VARCHAR2 (10 Byte) 
INITIAL_PLAN_SUB_TYPE 44 VARCHAR2 (10 Byte) 
INTERIM_PAYMENT_TYPE 45 VARCHAR2 (10 Byte) 
INTERIM_BADMIN_NAME 46 VARCHAR2 (250 Byte) 
INTERIM_MCO_NAME 47 VARCHAR2 (250 Byte) 
INTERIM_PLAN_NAME 48 VARCHAR2 (250 Byte) 
INTERIM_PLAN_TYPE 49 VARCHAR2 (10 Byte) 
INTERIM_PLAN_SUB_TYPE 50 VARCHAR2 (10 Byte) 
FINAL_PAYMENT_TYPE 51 VARCHAR2 (10 Byte) 
FINAL_BADMIN_NAME 52 VARCHAR2 (250 Byte) 
FINAL_MCO_NAME 53 VARCHAR2 (250 Byte) 
FINAL_PLAN_NAME 54 VARCHAR2 (250 Byte) 
FINAL_PLAN_TYPE 55 VARCHAR2 (10 Byte) 
FINAL_PLAN_SUB_TYPE 56 VARCHAR2 (10 Byte) 
INITIAL_CLAIM_STATUS 57 CHAR (8 Byte) 
INITIAL_REJECT_CDE 58 VARCHAR2 (10 Byte) 
INITIAL_REJECT_REASON 59 VARCHAR2 (100 Byte) 
INITIAL_REJECT_GROUP 60 VARCHAR2 (60 Byte) 
INITIAL_MACRO_REJ_GROUP 61 VARCHAR2 (13 Byte) 
INITIAL_SOB 62 VARCHAR2 (13 Byte) 
INTERIM_CLAIM_STATUS 63 CHAR (8 Byte) 
INTERIM_REJECT_CDE 64 VARCHAR2 (10 Byte) 
INTERIM_REJECT_REASON 65 VARCHAR2 (100 Byte) 
INTERIM_REJECT_GROUP 66 VARCHAR2 (60 Byte) 
INTERIM_MACRO_REJ_GROUP 67 VARCHAR2 (13 Byte) 
INTERIM_SOB 68 VARCHAR2 (13 Byte) 
FINAL_CLAIM_STATUS 69 CHAR (8 Byte) 
FINAL_REJECT_CDE 70 VARCHAR2 (10 Byte) 
FINAL_REJECT_REASON 71 VARCHAR2 (100 Byte) 
FINAL_REJECT_GROUP 72 VARCHAR2 (60 Byte) 
FINAL_MACRO_REJ_GROUP 73 VARCHAR2 (13 Byte) 
FINAL_SOB 74 VARCHAR2 (13 Byte) 
INTERIM_TIME_TO_FILL 75 NUMBER 
FINAL_TIME_TO_FILL 76 NUMBER 
MEDICARE_ELIGIBILITY 77 VARCHAR2 (11 Byte) 
INITIAL_APP_CLAIM_CNT 78 NUMBER 
INITIAL_REJ_CLAIM_CNT 79 NUMBER 
NN_INITIAL_APP_CLAIM_CNT 80 NUMBER 
60  
NNZ_INITIAL_APP_CLAIM_CNT 81 NUMBER 
INITIAL_APP_PAT_PAY 82 NUMBER 
INITIAL_PLAN_APP_PLAN_PAY 83 NUMBER 
INTERIM_APP_CLAIM_CNT 84 NUMBER 
INTERIM_REJ_CLAIM_CNT 85 NUMBER 
INTERIM_REV_CLAIM_CNT 86 NUMBER 
INTERIM_PLAN_APP_CLAIM_CNT 87 NUMBER 
NN_INTERIM_APP_CLAIM_CNT 88 NUMBER 
NNZ_INTERIM_APP_CLAIM_CNT 89 NUMBER 
NN_INTERIM_REV_CLAIM_CNT 90 NUMBER 
NNZ_INTERIM_REV_CLAIM_CNT 91 NUMBER 
NN_INTRM_PLN_APP_CLM_CNT 92 NUMBER 
NNZ_INTRM_PLN_APP_CLM_CNT 93 NUMBER 
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